06/08/23 1:09 AMNasdaq : IONS Ionis prices private placement of convertible senior notesIonis Pharmaceuticals, Inc. announced today the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144 A under the Securities Act of 1933, as amended. Ionis also granted the initial purchasers of...RHEA-AIneutral
06/06/23 4:01 PMNasdaq : IONS Ionis announces proposed private placement of convertible notesIonis Pharmaceuticals, Inc. announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144 A under the Securities Act of 1933, as...RHEA-AIneutral
06/01/23 7:05 AMNasdaq : IONS Ionis announces positive donidalorsen late-stage clinical progress in HAEIonis Pharmaceuticals, Inc. today announced positive clinical progress with...RHEA-AIneutral
05/10/23 7:05 AMNasdaq : IONS conferencesIonis to host 2023 virtual Annual Meeting of StockholdersIonis Pharmaceuticals, Inc. today announced that management will conduct its 2023 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 1, 2023.. The agenda for the event is as follows:. 5:00 p.m.– 5:15 p.m. ET– Virtual Annual Meeting of Stockholders All stockholders of record...RHEA-AIneutral
05/09/23 7:05 AMNasdaq : IONS conferencesIonis to present at upcoming investor conferencesIonis Pharmaceuticals, Inc. today announced that management will participate in fireside chats at the following investor conferences:. RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023. A live webcast of the...RHEA-AIneutral
05/03/23 7:00 AMNasdaq : IONS earningsIonis reports first quarter 2023 financial resultsIonis Pharmaceuticals, Inc., today reported financial results for the first quarter of 2023. Revenue for the first quarter of 2023 was in line with expectations and included revenue from numerous diverse sources Operating expenses increased in the first quarter of...RHEA-AIneutral
04/25/23 7:10 PMNasdaq : IONS fda approvalFDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALSIonis Pharmaceuticals, Inc. today announced that its partner Biogen has received U.S. Food and Drug Administration approval of QALSODY™ 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene. This indication is approved under accelerated approval based on a reduction in...RHEA-AIneutral
04/24/23 7:00 AMNasdaq : IONS clinical trialEplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeksNEURO-TTRansform study met all co-primary and secondary endpoints Positive results to be presented today at AAN 2023 demonstrate eplontersen efficacy, safety and administration profile may provide an important new treatment option in this fatal disease with significant unmet need Ionis to hostRHEA-AIpositive
04/20/23 7:05 AMNasdaq : IONS earningsIonis to hold first quarter 2023 financial results webcastIonis Pharmaceuticals, Inc. announced today that it will host a live webcast on Wednesday, May 3 rd at 11:30 a.m. Eastern Time to discuss its first quarter 2023 financial results. The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. About Ionis Pharmaceuticals, Inc. For more than 30 years, Ionis has been...RHEA-AIneutral
03/29/23 8:45 AMNasdaq : IONS New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's diseaseIonis Pharmaceuticals, Inc. today reported that its partner Biogen presented new Phase 1 b clinical data showing that IONIS-MAPT Rx reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease. The results were presented today at the International Conference on...RHEA-AIneutral